T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges in safety & efficacy, manufacture & scalability that are restraining the use of conventional CAR-T cells.
The T cell technology platform includes virus-free gene transfer and optimizes the binding of a chimeric-antigen-receptors to its antigen using a new and proprietary CAR format.
CAR-T cells are a transformative, one-shot, chemotherapy-free cancer treatment. Patient T cells are reprogrammed using gene transfer technology to destroy tumor cells. CAR-T cells are ‘living drugs’ that persist life-long and provide protection from relapse.
T-CURX’ target pipeline addresses several cancer indications such as multiple myeloma and acute myeloid leukemia (hematology), breast cancer, lung cancer and pancreatic cancer (oncology).